Metastatic Urothelial Cancer (DBCOND0066157)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Avelumab	An anti-PD-L1 monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.	Programmed cell death 1 ligand 1target
Doxorubicin	A medication used to treat various cancers, including AIDS-associated Kaposi's Sarcoma and metastatic cancers.	DNA topoisomerase 2-alphatarget DNAtarget Cytochrome P450 3A4enzyme Cytochrome P450 2D6enzyme Cytochrome P450 2B6enzyme ATP-dependent translocase ABCB1transporter ATP-binding cassette sub-family C member 3transporter ATP-binding cassette sub-family C member 6transporter Multidrug resistance-associated protein 1transporter ATP-binding cassette sub-family C member 10transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Bile salt export pumptransporter Solute carrier family 22 member 16transporter Mitochondrial potassium channel ATP-binding subunittransporter Cytochrome P450 1B1enzyme Carbonyl reductase [NADPH] 1enzyme Carbonyl reductase [NADPH] 3enzyme Aldo-keto reductase family 1 member A1enzyme Aldo-keto reductase family 1 member C3enzyme NAD(P)H dehydrogenase [quinone] 1enzyme Xanthine dehydrogenase/oxidaseenzyme Nitric oxide synthase 3enzyme Nitric oxide synthase, inducibleenzyme Nitric oxide synthase 1enzyme NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrialenzyme NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrialenzyme NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrialenzyme NADPH--cytochrome P450 reductaseenzyme RalA-binding protein 1transporter ATP-binding cassette sub-family C member 2transporter Albumincarrier Nucleolar and coiled-body phosphoprotein 1target DNA topoisomerase 1target DNA topoisomerase 2-betatarget Aldo-keto reductase family 1 member B1enzyme Aldo-keto reductase family 1 member B10enzyme Aldo-keto reductase family 1 member C4enzyme Telomerase reverse transcriptasetarget
Enfortumab vedotin	An antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer.	Cytochrome P450 3A4enzyme Nectin-4target ATP-dependent translocase ABCB1transporter

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06225596	Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)	Avelumab Carboplatin Cisplatin Gemcitabine Pembrolizumab	treatment	2 / 3	recruiting
NCT06505746	A Study of Real-world Treatment of Adults With Urothelial Cancer in South Korea and Saudi Arabia	No drug interventions	Not Available	Not Available	recruiting
NCT04995419	A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy	Enfortumab vedotin	treatment	2	active_not_recruiting
NCT05101096	Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors	Sacituzumab govitecan	treatment	1 / 2	active_not_recruiting
NCT05390645	A Study of MFA-370 in Patients with Metastatic Urothelial Cancer	No drug interventions	treatment	1 / 2	withdrawn
NCT03070990	A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma	Enfortumab vedotin	treatment	1	completed
NCT02826564	Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer	Pembrolizumab	treatment	1	completed
NCT03745911	Paclitaxel and TAK-228 in Urothelial Carcinoma	Paclitaxel Sapanisertib	treatment	2	unknown_status
NCT01963052	ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer	No drug interventions	treatment	1	completed
NCT03448718	Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations	Olaparib	treatment	2	completed
NCT02240017	A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.	Carboplatin Cisplatin Gemcitabine	treatment	2 / 3	completed
NCT03547973	Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread	Avelumab Carboplatin Cisplatin Domvanalimab Enfortumab vedotin Gemcitabine Pembrolizumab Sacituzumab govitecan Zimberelimab	treatment	2	recruiting
NCT03679767	A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)	Retifanlimab	treatment	2	completed
NCT03682068	Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer	Carboplatin Cisplatin Durvalumab Gemcitabine Tremelimumab	treatment	3	active_not_recruiting
NCT03451331	Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer	Carboplatin Gemcitabine Nivolumab Oxaliplatin	treatment	2	completed
NCT03390595	Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma	Avelumab Carboplatin Gemcitabine	treatment	2	completed